unc-5 family C-terminal likeGenealiases: MUXA · ZUD
Q-omics provides the consensus-scored UNC5CL profile across patient tissues and cancer cell-line models. UNC5CL expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, UNC5CL is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, UNC5CL RNA expression shows 17,946 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, HNSC, and UVM as cancer lineages where UNC5CL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UNC5CL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UNC5CL survival associations across molecular data types. UNC5CL RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UNC5CL RNA expression–survival associations across cancer types. High UNC5CL expression shows unfavorable associations in DLBC, but favorable associations in BLCA, MESO, UCS, HNSC and THYM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for UNC5CL RNA expression.
This table summarizes UNC5CL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UNC5CL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UNC5CL shows lower tumor expression in KICH and higher tumor expression in HNSC, THCA, COAD, LUAD and READ. The HNSC box plot shows higher UNC5CL RNA expression in tumor versus normal tissue (log2 FC = +0.519, t-test p < 0.001).
This table shows molecular features associated with UNC5CL in patient tissues and cancer cell lines. In patient samples, UNC5CL shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, UNC5CL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
